Elevation Begin Period Cash Flow from 2010 to 2025
| ELEV Stock | USD 0.26 0.02 7.14% |
Begin Period Cash Flow | First Reported 2020-03-31 | Previous Quarter 59.4 M | Current Value 48.2 M | Quarterly Volatility 44.1 M |
Check Elevation Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Elevation Oncology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 33.3 K, Interest Expense of 1.1 M or Selling General Administrative of 10.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.56. Elevation financial statements analysis is a perfect complement when working with Elevation Oncology Valuation or Volatility modules.
Elevation | Begin Period Cash Flow |
Latest Elevation Oncology's Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Elevation Oncology over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Elevation Oncology's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Elevation Oncology's overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Elevation Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 25,685,445 | |
| Geometric Mean | 5,556,295 | |
| Coefficient Of Variation | 164.42 | |
| Mean Deviation | 32,924,987 | |
| Median | 1,740,000 | |
| Standard Deviation | 42,231,209 | |
| Sample Variance | 1783.5T | |
| Range | 144.5M | |
| R-Value | 0.66 | |
| Mean Square Error | 1076.1T | |
| R-Squared | 0.44 | |
| Significance | 0.01 | |
| Slope | 5,862,684 | |
| Total Sum of Squares | 26752.1T |
Elevation Begin Period Cash Flow History
About Elevation Oncology Financial Statements
Elevation Oncology investors use historical fundamental indicators, such as Elevation Oncology's Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Elevation Oncology. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 49.3 M | 71 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.